Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial
Introduction Vasodilatory hypotension is common among intensive care unit (ICU) patients; vasopressors are considered standard of care. However, optimal mean arterial pressure (MAP) targets for vasopressor titration are unknown. The objective of the Optimal VAsopressor TitraTION in patients 65 years...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/11/e037947.full |
id |
doaj-0cacd6fdb8f54f228139a915cadbc18e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sangeeta Mehta François Lauzier Emmanuel Charbonney Michaël Chasse Marie-Claude Battista Emilie Belley-Cote Brian H Cuthbertson Andreas Laupacis Alexis F Turgeon Frédérick D'Aragon Tina Millen Laveena Munshi Sumesh Shah Alexis Turgeon David Bellemare Eve Cloutier Marjorie Daigle Stéphanie Grenier Gabrielle Guilbault Sydney Miezitis Rebecca Porteous Irene Watpool Karolina Walczak Frédérick D’Aragon Charles St-Arnaud Elaine Carbonneau Joannie Marchand Marie-Hélène Masse Fatna Benettaib Dounia Boumahni Marie-Ève Cantin Ali Ghamraoui Martine Lebrasseur Maya Salame Navjot Kaur Nicole Marinoff Guillaume Leblanc Mary Elizabeth Wilcox Ruxandra Pinto Michael Mayette Marc-André Leclair Hector Quiroz Martinez Brian Grondin-Beaudoin Yannick Poulin Andrew J E Seely Édouard Botton Dian Cohen Neill K J Adhikari Neill KJ Adhikari Lauren Griffith Scott Halpern Louise Robert-Petit Marie-Ève Thibault François-Michel Boisvert Lee Hwa Tai Jean-Luc Parent Xavier Roucou Hector Quiroz-Martinez Line Côté Marilène Ladouceur Noémie Turcotte Andrew Seely Andre Carlos Amaral Wael Mohammed Charles Francoeur Olivier Costerousse Isabelle St-Hilaire Jeffrey Singh |
spellingShingle |
Sangeeta Mehta François Lauzier Emmanuel Charbonney Michaël Chasse Marie-Claude Battista Emilie Belley-Cote Brian H Cuthbertson Andreas Laupacis Alexis F Turgeon Frédérick D'Aragon Tina Millen Laveena Munshi Sumesh Shah Alexis Turgeon David Bellemare Eve Cloutier Marjorie Daigle Stéphanie Grenier Gabrielle Guilbault Sydney Miezitis Rebecca Porteous Irene Watpool Karolina Walczak Frédérick D’Aragon Charles St-Arnaud Elaine Carbonneau Joannie Marchand Marie-Hélène Masse Fatna Benettaib Dounia Boumahni Marie-Ève Cantin Ali Ghamraoui Martine Lebrasseur Maya Salame Navjot Kaur Nicole Marinoff Guillaume Leblanc Mary Elizabeth Wilcox Ruxandra Pinto Michael Mayette Marc-André Leclair Hector Quiroz Martinez Brian Grondin-Beaudoin Yannick Poulin Andrew J E Seely Édouard Botton Dian Cohen Neill K J Adhikari Neill KJ Adhikari Lauren Griffith Scott Halpern Louise Robert-Petit Marie-Ève Thibault François-Michel Boisvert Lee Hwa Tai Jean-Luc Parent Xavier Roucou Hector Quiroz-Martinez Line Côté Marilène Ladouceur Noémie Turcotte Andrew Seely Andre Carlos Amaral Wael Mohammed Charles Francoeur Olivier Costerousse Isabelle St-Hilaire Jeffrey Singh Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial BMJ Open |
author_facet |
Sangeeta Mehta François Lauzier Emmanuel Charbonney Michaël Chasse Marie-Claude Battista Emilie Belley-Cote Brian H Cuthbertson Andreas Laupacis Alexis F Turgeon Frédérick D'Aragon Tina Millen Laveena Munshi Sumesh Shah Alexis Turgeon David Bellemare Eve Cloutier Marjorie Daigle Stéphanie Grenier Gabrielle Guilbault Sydney Miezitis Rebecca Porteous Irene Watpool Karolina Walczak Frédérick D’Aragon Charles St-Arnaud Elaine Carbonneau Joannie Marchand Marie-Hélène Masse Fatna Benettaib Dounia Boumahni Marie-Ève Cantin Ali Ghamraoui Martine Lebrasseur Maya Salame Navjot Kaur Nicole Marinoff Guillaume Leblanc Mary Elizabeth Wilcox Ruxandra Pinto Michael Mayette Marc-André Leclair Hector Quiroz Martinez Brian Grondin-Beaudoin Yannick Poulin Andrew J E Seely Édouard Botton Dian Cohen Neill K J Adhikari Neill KJ Adhikari Lauren Griffith Scott Halpern Louise Robert-Petit Marie-Ève Thibault François-Michel Boisvert Lee Hwa Tai Jean-Luc Parent Xavier Roucou Hector Quiroz-Martinez Line Côté Marilène Ladouceur Noémie Turcotte Andrew Seely Andre Carlos Amaral Wael Mohammed Charles Francoeur Olivier Costerousse Isabelle St-Hilaire Jeffrey Singh |
author_sort |
Sangeeta Mehta |
title |
Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial |
title_short |
Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial |
title_full |
Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial |
title_fullStr |
Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial |
title_full_unstemmed |
Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial |
title_sort |
optimal vasopressor titration in patients 65 years and older (ovation-65): protocol and statistical analysis plan for a randomised clinical trial |
publisher |
BMJ Publishing Group |
series |
BMJ Open |
issn |
2044-6055 |
publishDate |
2020-11-01 |
description |
Introduction Vasodilatory hypotension is common among intensive care unit (ICU) patients; vasopressors are considered standard of care. However, optimal mean arterial pressure (MAP) targets for vasopressor titration are unknown. The objective of the Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65) trial is to ascertain the effect of permissive hypotension (vasopressor titration to achieve MAP 60–65 mm Hg) versus usual care on biomarkers of organ injury in hypotensive patients aged ≥65 years.Methods and analysis OVATION-65 is an allocation-concealed randomised trial in 7 Canadian hospitals. Eligible patients are ≥65 years of age, in an ICU with vasodilatory hypotension, receiving vasopressors for ≤12 hours to maintain MAP ≥65 mm Hg during or after adequate fluid resuscitation, and expected to receive vasopressors for ≥6 additional hours. Patients are excluded for any of the following: active treatment for spinal cord or acute brain injury; vasopressors given solely for bleeding, ventricular failure or postcardiopulmonary bypass vasoplegia; withdrawal of life-sustaining treatments expected within 48 hours; death perceived as imminent; previous enrolment in OVATION-65; organ transplant within the last year; receiving extracorporeal life support or lack of physician equipoise. Patients are randomised to permissive hypotension versus usual care for up to 28 days. The primary outcome is high-sensitivity troponin T, a biomarker of cardiac injury, on day 3. Secondary outcomes include biomarkers of injury to other organs (brain, liver, intestine, skeletal muscle); lactate (a biomarker of global tissue dysoxia); resource utilisation; adverse events; mortality (90 days and 6 months) and cognitive function (6 months). Assessors of biomarkers, mortality and cognitive function are blinded to allocation.Ethics and dissemination This protocol has been approved at all sites. Consent is obtained from the eligible patient, the substitute decision-maker if the patient is incapable, or in a deferred fashion where permitted. End-of-grant dissemination plans include presentations, publications and social media platforms and discussion forums.Trial registration number NCT03431181. |
url |
https://bmjopen.bmj.com/content/10/11/e037947.full |
work_keys_str_mv |
AT sangeetamehta optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT francoislauzier optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT emmanuelcharbonney optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT michaelchasse optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marieclaudebattista optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT emiliebelleycote optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT brianhcuthbertson optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT andreaslaupacis optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT alexisfturgeon optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT frederickdaragon optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT tinamillen optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT laveenamunshi optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT sumeshshah optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT alexisturgeon optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT davidbellemare optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT evecloutier optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marjoriedaigle optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT stephaniegrenier optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT gabrielleguilbault optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT sydneymiezitis optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT rebeccaporteous optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT irenewatpool optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT karolinawalczak optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT frederickdaragon optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT charlesstarnaud optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT elainecarbonneau optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT joanniemarchand optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT mariehelenemasse optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT fatnabenettaib optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT douniaboumahni optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marieevecantin optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT alighamraoui optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT martinelebrasseur optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT mayasalame optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT navjotkaur optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT nicolemarinoff optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT guillaumeleblanc optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT maryelizabethwilcox optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT ruxandrapinto optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT michaelmayette optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marcandreleclair optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT hectorquirozmartinez optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT briangrondinbeaudoin optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT yannickpoulin optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT andrewjeseely optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT edouardbotton optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT diancohen optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT neillkjadhikari optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT neillkjadhikari optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT laurengriffith optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT scotthalpern optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT louiserobertpetit optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marieevethibault optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT francoismichelboisvert optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT leehwatai optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT jeanlucparent optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT xavierroucou optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT hectorquirozmartinez optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT linecote optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT marileneladouceur optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT noemieturcotte optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT andrewseely optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT andrecarlosamaral optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT waelmohammed optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT charlesfrancoeur optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT oliviercosterousse optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT isabellesthilaire optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial AT jeffreysingh optimalvasopressortitrationinpatients65yearsandolderovation65protocolandstatisticalanalysisplanforarandomisedclinicaltrial |
_version_ |
1721359752831696896 |
spelling |
doaj-0cacd6fdb8f54f228139a915cadbc18e2021-06-25T12:34:38ZengBMJ Publishing GroupBMJ Open2044-60552020-11-01101110.1136/bmjopen-2020-037947Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trialSangeeta Mehta0François Lauzier1Emmanuel Charbonney2Michaël Chasse3Marie-Claude Battista4Emilie Belley-Cote5Brian H Cuthbertson6Andreas Laupacis7Alexis F Turgeon8Frédérick D'Aragon9Tina Millen10Laveena MunshiSumesh ShahAlexis TurgeonDavid Bellemare11Eve CloutierMarjorie DaigleStéphanie GrenierGabrielle GuilbaultSydney MiezitisRebecca Porteous12Irene Watpool13Karolina WalczakFrédérick D’Aragon14Charles St-Arnaud15Elaine Carbonneau16Joannie MarchandMarie-Hélène Masse17Fatna BenettaibDounia BoumahniMarie-Ève CantinAli GhamraouiMartine Lebrasseur18Maya SalameNavjot KaurNicole Marinoff19Guillaume Leblanc20Mary Elizabeth Wilcox21Ruxandra Pinto22Michael Mayette23Marc-André Leclair24Hector Quiroz Martinez25Brian Grondin-Beaudoin26Yannick Poulin27Andrew J E Seely28Édouard Botton29Dian Cohen30Neill K J Adhikari31Neill KJ AdhikariLauren GriffithScott Halpern32Louise Robert-PetitMarie-Ève ThibaultFrançois-Michel BoisvertLee Hwa TaiJean-Luc ParentXavier RoucouHector Quiroz-MartinezLine CôtéMarilène LadouceurNoémie TurcotteAndrew Seely33Andre Carlos AmaralWael MohammedCharles FrancoeurOlivier CosterousseIsabelle St-HilaireJeffrey SinghInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, CanadaPopulation Health and Optimal Health Practices Research Unit, Centre de recherche du CHU de Québec-Université Laval, Quebec, Quebec, CanadaDepartment of Medicine, Université de Montréal, Montreal, Quebec, CanadaDepartment of Medicine, Université de Montréal, Montreal, Quebec, CanadaCentre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, CanadaDepartment of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada6 Critical Care Medicine, Sunnnybrook Health Sciences Centre, Toronto, Ontario, Canada 4 Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Population Health and Optimal Health Practices Research Unit, Centre de recherche du CHU de Québec-Université Laval, Quebec, Quebec, CanadaDepartment of Anesthesiology, Universite de Sherbrooke Faculte de Medecine et des Sciences de la Sante, Sherbrooke, Québec, Canada1 Department of Medicine, Division of Critical Care, McMaster University, Hamilton, Ontario, CanadaPopulation Health and Optimal Health Practices Research Unit, Centre de recherche du CHU de Québec-Université Laval, Quebec, Quebec, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, CanadaOttawa Hospital Research Institute, Ottawa, Ontario, Canada3 Department of Anaesthesiology, Université de Sherbrooke, Sherbrooke, Québec, Canada Centre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, CanadaCentre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, CanadaCentre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, CanadaCentre de recherche, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, CanadaDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaCHU de Québec – Université Laval Research Center, Population Health and Optimal Health Practices Research Unit (Trauma-Emergency-Critical Care Medicine), Université Laval, Quebec City, Quebec, CanadaInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, CanadaDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaCentre de recherche, Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, CanadaDepartment of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, CanadaDepartment of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, CanadaDepartment of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, CanadaDepartment of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, CanadaDepartments of Surgery and Critical Care Medicine, University of Ottawa, Ottawa, Ontario, CanadaPatient partners, Sherbrooke, Quebec, CanadaPatient partners, Sherbrooke, Quebec, CanadaDepartment of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada1US University of Pennsylvania Perelman School of Medicine4Departments of Surgery and Critical Care Medicine, Faculty of Medicine and Dentistry, University of Ottawa, Ottawa, CanadaIntroduction Vasodilatory hypotension is common among intensive care unit (ICU) patients; vasopressors are considered standard of care. However, optimal mean arterial pressure (MAP) targets for vasopressor titration are unknown. The objective of the Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65) trial is to ascertain the effect of permissive hypotension (vasopressor titration to achieve MAP 60–65 mm Hg) versus usual care on biomarkers of organ injury in hypotensive patients aged ≥65 years.Methods and analysis OVATION-65 is an allocation-concealed randomised trial in 7 Canadian hospitals. Eligible patients are ≥65 years of age, in an ICU with vasodilatory hypotension, receiving vasopressors for ≤12 hours to maintain MAP ≥65 mm Hg during or after adequate fluid resuscitation, and expected to receive vasopressors for ≥6 additional hours. Patients are excluded for any of the following: active treatment for spinal cord or acute brain injury; vasopressors given solely for bleeding, ventricular failure or postcardiopulmonary bypass vasoplegia; withdrawal of life-sustaining treatments expected within 48 hours; death perceived as imminent; previous enrolment in OVATION-65; organ transplant within the last year; receiving extracorporeal life support or lack of physician equipoise. Patients are randomised to permissive hypotension versus usual care for up to 28 days. The primary outcome is high-sensitivity troponin T, a biomarker of cardiac injury, on day 3. Secondary outcomes include biomarkers of injury to other organs (brain, liver, intestine, skeletal muscle); lactate (a biomarker of global tissue dysoxia); resource utilisation; adverse events; mortality (90 days and 6 months) and cognitive function (6 months). Assessors of biomarkers, mortality and cognitive function are blinded to allocation.Ethics and dissemination This protocol has been approved at all sites. Consent is obtained from the eligible patient, the substitute decision-maker if the patient is incapable, or in a deferred fashion where permitted. End-of-grant dissemination plans include presentations, publications and social media platforms and discussion forums.Trial registration number NCT03431181.https://bmjopen.bmj.com/content/10/11/e037947.full |